Genetically Engineered Nanoparticles of Asymmetric Triblock Polypeptide with a Platinum(IV) Cargo Outperforms a Platinum(II) Analog and Free Drug in a Murine Cancer Model
- 15 July 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 22 (14) , 5898-5908
Abstract
Despite the widespread use of platinum(Pt)-drugs for cancer-therapy, their development has stalled, as no new Pt-drugs have been approved in over a decade. Packaging small molecule drugs into nanoparticles is a way to enhance their therapeutic efficacy. However, an important consideration in designing Pt-nanoparticles, and the focus of this study, is the rational choice of oxidation-state of Pt. To date, there has been no direct comparison of relative merits of the choice of Pt oxidation-state in the same nanoparticle-system that would allow its optimal design. To address this lacuna, we designed an recombinant asymmetric triblock polypeptide (ATBP) that self-assembles into rod-shaped micelles and chelates Pt(II) or enable covalent conjugation of Pt(IV) with similar morphology and stability. Both ATBP-Pt(II) and ATBP-Pt(IV) nanoparticles enhanced the half-life of Pt by ~45-fold but ATBP-Pt(IV) had superior tumor regression efficacy compared to ATBP-Pt(II) and cisplatin. These results suggest loading Pt(IV) into genetically engineered nanoparticles may yield a new generation of more effective platinum-drug nanoformulations.Keywords
Funding Information
- National Institute of General Medical Sciences (R35GM127042)
- Dr. Reddy?s laboratory
This publication has 48 references indexed in Scilit:
- Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicityProceedings of the National Academy of Sciences, 2012
- The status of platinum anticancer drugs in the clinic and in clinical trialsDalton Transactions, 2010
- Self-assembling chimeric polypeptide–doxorubicin conjugate nanoparticles that abolish tumours after a single injectionNature Materials, 2009
- Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) WarheadsJournal of the American Chemical Society, 2009
- Dose Escalation Methods in Phase I Cancer Clinical TrialsJNCI: Journal of the National Cancer Institute, 2009
- Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticlesProceedings of the National Academy of Sciences, 2008
- A glucose derivative as natural alternative to the cyclohexane‐1,2‐diamine ligand in the anticancer drug oxaliplatin?ChemMedChem, 2007
- Automated Parallel Solid-Phase Synthesis and Anticancer Screening of a Library of Peptide-Tethered Platinum(II) ComplexesJournal of Combinatorial Chemistry, 2003
- HPMA Copolymers Platinates Containing Dicarboxylato Ligands. Preparation, Characterisation and In Vitro and In Vivo EvaluationJournal of Drug Targeting, 2002
- Stability of Chelate ComplexesNature, 1949